News for ProQR Therapeutics B.V.

TipRanks 6d

Citizens JMP Reaffirms Their Buy Rating on ProQR (PRQR)

TipRanks 6d

Cantor Fitzgerald Remains a Buy on ProQR (PRQR)

GlobeNewswire 6d

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

TipRanks 51d

ProQR Therapeutics price target lowered to $9 from $15 at Oppenheimer

GlobeNewswire 52d

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

GlobeNewswire 56d

ProQR Announces First Quarter 2025 Operating and Financial Results

Seeking Alpha 56d

ProQR GAAP EPS of -€0.10, revenue of €4.52M

TipRanks 56d

ProQR Therapeutics reports Q1 EPS (EUR 0.10) vs (EUR 0.09) last year

GlobeNewswire 62d

ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

GlobeNewswire 63d

ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

TipRanks 65d

ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald

TipRanks 65d

ProQR Therapeutics initiated with an Outperform at Evercore ISI

GlobeNewswire 80d

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

TipRanks 80d

ProQR Therapeutics appoints Hom as CFO, Lopez as CMO

TipRanks 111d

ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright

TipRanks 111d

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and ProQR (PRQR)

TipRanks 112d

ProQR Therapeutics files to sell 3.52M ordinary shares for holders

GlobeNewswire 112d

ProQR Announces Year End 2024 Operating and Financial Results

Seeking Alpha 112d

ProQR GAAP EPS of -$0.32

TipRanks 112d

ProQR Therapeutics reports FY24 EPS (EUR 0.32) vs (EUR 0.35) last year

TipRanks 117d

ProQR Therapeutics upgraded to Buy from Neutral at Citi

TipRanks 141d

ProQR Therapeutics initiated with a Buy at JonesResearch

TipRanks 171d

ProQR’s Strategic Focus on RNA Editing for Liver Disease: Targeting PNPLA3 in the MASH Space

TipRanks 174d

Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and ProQR (PRQR)

TipRanks 174d

ProQR Therapeutics initiated with an Outperform at Oppenheimer

TipRanks 203d

ProQR’s Strategic Advancements and Financial Stability Drive ‘Buy’ Rating

TipRanks 203d

ProQR’s Strategic Positioning in RNA Editing Technology: A Buy Recommendation

TipRanks 203d

ProQR’s Promising RNA-Editing Advancements and Strategic Collaborations Drive Buy Rating

TipRanks 203d

ProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic Partnerships

GlobeNewswire 204d

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

TipRanks 204d

ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy

TipRanks 204d

ProQR Therapeutics announces $8.1M in new funding from RSRT

GlobeNewswire 205d

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

TipRanks 205d

ProQR Strengthens RNA Editing Team with Key Appointment

TipRanks 205d

ProQR Therapeutics appoints Beal as Chief ADAR Scientist

GlobeNewswire 210d

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

TipRanks 210d

ProQR Highlights RNA Innovations in Upcoming Event

TipRanks 210d

ProQR Therapeutics price target raised to $8 from $5 at JMP Securities

TipRanks 224d

ProQR Therapeutics Highlights Q3 2024 Financial Results

TipRanks 237d

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan

TipRanks 237d

ProQR: Buy Rating Affirmed on Promising RNA Base-Editing Technology and Strong Financial Position

GlobeNewswire 238d

ProQR Announces Third Quarter 2024 Operating and Financial Results

TipRanks 238d

ProQR Therapeutics Shows Revenue Growth Amid Financial Challenges

TipRanks 238d

ProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last year

TipRanks 238d

ProQR Therapeutics sees cash runway into mid-2027

TipRanks 247d

Trade Desk downgraded, First Solar upgraded: Wall Street’s top analyst calls

TipRanks 247d

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

GlobeNewswire 250d

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

TipRanks 250d

ProQR Announces Major Share Offering Agreement

TipRanks 253d

Largest borrow rate increases among liquid names

	
		OSZAR »